EP08.02-104 Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World

M Lorenzi,D Scattolin,A Del Conte,S Sangiorgi,V Polo,A Pavan,S Pilotto,M Santarpia,V Da Ros,A Dal Maso,A Ferro,S Frega,A Bortolami,L Bonanno,S Indraccolo,V Guarneri,G Pasello

doi:10.1016/j.jtho.2022.07.787

EP08.02-104 Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World

M Lorenzi, D Scattolin + Show 15 more

Open Access

https://doi.org/10.1016/j.jtho.2022.07.787

Copy DOI

Journal: Journal of Thoracic Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Istituto Oncologico Veneto, Ca' Foncello Hospital, Azienda Ospedaliera Universitaria Integrata Verona, University of Padua, Centro di Riferimento Oncologico, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Ospedale dell' Angelo

#EGFR-mutant Non-small Cell Lung Cancers #Safety Of Osimertinib + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The observational prospective multicenter FLOWER study (NCT04965701) confirmed effectiveness and safety of osimertinib in the real-world (RW) management of untreated EGFR-mutant advanced non-small cell lung cancer (aNSCLC) patients (Lorenzi M. et al., The Oncologist, 2021, DOI:https://doi.org/10.1002/onco.13951). Herein, we report updated effectiveness data, post-progression diagnostic-therapeutic pathway and the budget impact (BI) of osimertinib on the national health system (NHS).

Full Text